Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
about
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.The rise of genomic profiling in ovarian cancer.
P2860
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Expected benefits of topotecan ...... ical profile: a phase 2 trial.
@ast
Expected benefits of topotecan ...... ical profile: a phase 2 trial.
@en
type
label
Expected benefits of topotecan ...... ical profile: a phase 2 trial.
@ast
Expected benefits of topotecan ...... ical profile: a phase 2 trial.
@en
prefLabel
Expected benefits of topotecan ...... ical profile: a phase 2 trial.
@ast
Expected benefits of topotecan ...... ical profile: a phase 2 trial.
@en
P2093
P1476
Expected benefits of topotecan ...... ical profile: a phase 2 trial.
@en
P2093
Alain Lortholary
Alexandra Leconte
Anne Plantade
Béatrice Weber
Bénédicte Clarisse
Cécile Blanc-Fournier
Frédéric Selle
Hugues Bourgeois
Michel Fabbro
Mélanie Briand
P304
P356
10.1097/IGC.0B013E31826D1438
P577
2012-11-01T00:00:00Z